Other News To Note
Wednesday, August 24, 2011
Cel-Sci Corp., of Vienna, Va., inked a sales, marketing and distribution agreement granting IDC-GP Pharm LLC an exclusive license to cancer therapy Multikine (leukocyte interleukin injection) in Argentina and Venezuela. IDC-GP is a joint venture between two pharmaceutical entrepreneurs with expertise in registration and commercialization in South America. Under the terms, IDC-GP will be responsible for seeking regulatory approval of Multikine and commercializing the drug in its territories, with revenues split 50-50 with Cel-Sci after payment for manufacturing costs. Specific terms were not disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.